Human immunodeficiency virus protease inhibitors

被引:26
|
作者
Rana, KZ
Dudley, MN
机构
[1] Univ Rhode Isl, Coll Pharm, Roger Williams Med Ctr, Antiinfect Pharmacol Res Unit, Providence, RI 02908 USA
[2] Microcide Pharmaceut, Mountain View, CA USA
来源
PHARMACOTHERAPY | 1999年 / 19卷 / 01期
关键词
D O I
10.1592/phco.19.1.35.30513
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human immunodeficiency virus (HIV) protease inhibitors have revolutionized the treatment of individuals infected with this pathogen. The protease is an enzyme that is essential for viral replication because it cleaves both structural and functional proteins from precursor viral polyprotein strands. Inhibition of this process suppresses viral replication, which produces immature noninfectious virions. When combined with reverse transcriptase inhibitors, these agents are very potent in suppressing viral replication. Pharmacologic properties, toxic profile, drug interactions, and resistance patterns differ among protease inhibitors, and all must be considered when selecting the drugs for therapeutic use in humans. The best combination, sequence of use, durability of response, and magnitude of immune reconstitution and function are issues that have yet to be fully elucidated.
引用
收藏
页码:35 / 59
页数:25
相关论文
共 50 条
  • [1] Protease inhibitors of the human immunodeficiency virus
    Roca, B
    Simon, E
    [J]. MEDICINA CLINICA, 1998, 110 (10): : 375 - 377
  • [2] Human immunodeficiency virus protease inhibitors
    Kline, MW
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (12) : 1085 - 1087
  • [3] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE
    TYAGI, SC
    [J]. BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1992, 70 (05): : 309 - 315
  • [4] Protease inhibitors for the treatment of human immunodeficiency virus infection
    Kakuda, TN
    Struble, KA
    Piscitelli, SC
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (03) : 233 - 254
  • [5] Human immunodeficiency virus protease inhibitors and Pneumocystis carinii
    Atzori, C
    Cargnel, A
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (11): : 1692 - 1693
  • [6] Human immunodeficiency virus type 1 protease inhibitors
    McDonald, CK
    Kuritzkes, DR
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (09) : 951 - 959
  • [7] Intracellular accumulation of human immunodeficiency virus protease inhibitors
    Khoo, SH
    Hoggard, PG
    Williams, I
    Meaden, ER
    Newton, P
    Wilkins, EG
    Smith, A
    Tjia, JF
    Lloyd, J
    Jones, K
    Beeching, N
    Carey, P
    Peters, B
    Back, DJ
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (10) : 3228 - 3235
  • [8] Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors
    Acosta, EP
    Kakuda, TN
    Brundage, RC
    Anderson, PL
    Fletcher, CV
    [J]. CLINICAL INFECTIOUS DISEASES, 2000, 30 : S151 - S159
  • [9] Human Immunodeficiency Virus Protease Inhibitors and Risk for Peripheral Neuropathy
    Ellis, Ronald J.
    Marquie-Beck, Jennifer
    Delaney, Patrick
    Alexander, Terry
    Clifford, David B.
    McArthur, Justin C.
    Simpson, David M.
    Ake, Christopher
    Collier, Ann C.
    Gelman, Benjamin B.
    McCutchan, J. Allen
    Morgello, Susan
    Grant, Igor
    [J]. ANNALS OF NEUROLOGY, 2008, 64 (05) : 566 - 572
  • [10] Factors associated with resistance to human immunodeficiency virus protease inhibitors
    Moltó, J
    Gutiérrez, F
    Mora, A
    Masiá, MD
    Escolano, C
    González, E
    Padilla, S
    Córdoba, J
    Hidalgo, AM
    [J]. MEDICINA CLINICA, 2002, 118 (19): : 721 - 724